Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA |
| gptkbp:ATCCode |
L01FX25
|
| gptkbp:brand |
Epkinly
|
| gptkbp:CASNumber |
2228327-56-0
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:AbbVie
gptkb:Genmab |
| https://www.w3.org/2000/01/rdf-schema#label |
Epcoritamab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CD3xCD20 bispecific antibody
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
fatigue
infections cytokine release syndrome injection site reactions pyrexia |
| gptkbp:target |
gptkb:CD20
gptkb:CD3 |
| gptkbp:UNII |
6Q1K1Q1K1F
|
| gptkbp:usedFor |
treatment of diffuse large B-cell lymphoma
treatment of follicular lymphoma |
| gptkbp:bfsParent |
gptkb:Genmab
|
| gptkbp:bfsLayer |
7
|